SP1 and cancer: Additionally, the signaling inhibitor MTR has been tested for cancer therapy since the 1960s due to its ability to prevent SP1 and SP3 binding but has never been accepted for cancer treatment due to its broad-spectrum effects in blocking RNA and protein synthesis62, resulting in side effects including hepatoxicity, gastrointestinal symptoms, and renal toxicity62.